Literature DB >> 24012882

Inhibition of influenza hemagglutinin with the antiviral inhibitor arbidol using a proteomics based approach and mass spectrometry.

Zainab H Nasser1, Kavya Swaminathan, Patrick Müller, Kevin M Downard.   

Abstract

A proteomics gel electrophoresis based approach has been applied to study the effect of arbidol on the proliferation of influenza virus in vitro through quantitation of hemagglutinin levels. An arbidol concentration of 20μg/ml was required to achieve a 50% reduction in virus proliferation and hemagglutinin levels. The use of a MALDI mass spectrometry approach to study the binding of arbidol to influenza hemagglutinin revealed it bound solely to residues 104-120 of the HA2 subunit, a region known to contain an arbidol resistance mutation. Parallel molecular docking results revealed that this binding site was favoured in which the arbidol molecule binds in two possible orientations approximately 180° to one another at HA2 residues 118-123. The combined studies support the recognized potential of arbidol as an effective and targeted antiviral agent against the influenza virus.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral inhibitor; Arbidol; Gel electrophoresis; Hemagglutinin; Influenza virus

Mesh:

Substances:

Year:  2013        PMID: 24012882     DOI: 10.1016/j.antiviral.2013.08.021

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  12 in total

1.  Molecular basis of influenza hemagglutinin inhibition with an entry-blocker peptide by computational docking and mass spectrometry.

Authors:  Robert Lu; Patrick Müller; Kevin M Downard
Journal:  Antivir Chem Chemother       Date:  2016-01-12

2.  Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol.

Authors:  Rameshwar U Kadam; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-21       Impact factor: 11.205

3.  Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin.

Authors:  Zoë V F Wright; Nicholas C Wu; Rameshwar U Kadam; Ian A Wilson; Dennis W Wolan
Journal:  Bioorg Med Chem Lett       Date:  2017-06-28       Impact factor: 2.823

Review 4.  Influenza Virus Entry inhibitors.

Authors:  Jie Yang; Shuwen Liu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses.

Authors:  Eve-Isabelle Pécheur; Viktoriya Borisevich; Peter Halfmann; John D Morrey; Donald F Smee; Mark Prichard; Chad E Mire; Yoshihiro Kawaoka; Thomas W Geisbert; Stephen J Polyak
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

6.  Quadruple therapy for asymptomatic COVID-19 infection patients.

Authors:  Ling Wang; Xiaopeng Xu; Junshan Ruan; Saijin Lin; Jinhua Jiang; Hong Ye
Journal:  Expert Rev Anti Infect Ther       Date:  2020-05-03       Impact factor: 5.091

Review 7.  Arbidol as a broad-spectrum antiviral: an update.

Authors:  Julie Blaising; Stephen J Polyak; Eve-Isabelle Pécheur
Journal:  Antiviral Res       Date:  2014-04-24       Impact factor: 5.970

8.  Study on the Antiviral Activities and Hemagglutinin-Based Molecular Mechanism of Novel Chlorogenin 3-O-β-Chacotrioside Derivatives Against H5N1 Subtype Viruses.

Authors:  Wan-Zhen Shi; Ling-Zhi Jiang; Gao-Peng Song; Sheng Wang; Ping Xiong; Chang-Wen Ke
Journal:  Viruses       Date:  2020-03-11       Impact factor: 5.048

9.  The Antiviral Drug Arbidol Inhibits Zika Virus.

Authors:  Susan L Fink; Lucia Vojtech; Jessica Wagoner; Natalie S J Slivinski; Konner J Jackson; Ruofan Wang; Sudip Khadka; Priya Luthra; Christopher F Basler; Stephen J Polyak
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

10.  The Location of the Protonated and Unprotonated Forms of Arbidol in the Membrane: A Molecular Dynamics Study.

Authors:  Vicente Galiano; José Villalaín
Journal:  J Membr Biol       Date:  2016-02-03       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.